Evidence map›Paper›PMID 26313448›Full record

ArticlePloS one2015

Development of Photodynamic Antimicrobial Chemotherapy (PACT) for Clostridium difficile.

Luisa De Sordi, M Adil Butt, Hayley Pye, Darina Kohoutova, Charles A Mosse, Gokhan Yahioglu, Ioanna Stamati, Mahendra Deonarain, Sinan Battah, Derren Ready and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 26 citations in OpenAlex.

  1. Clostridioides difficile Biofilm.Advances in experimental medicine and biology · 2024
    Article
  2. Article
  3. Review
  4. SensitizingPathogens & immunity · 2017
    Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Luisa De SordiMicrobial Diseases, UCL Eastman Dental Institute, London, United Kingdom; Research Department of Tissue & Energy, UCL, London, United Kingdom.
M Adil ButtResearch Department of Tissue & Energy, UCL, London, United Kingdom; Division of Gastrointestinal Services, University College Hospital, London, United Kingdom.
Hayley PyeResearch Department of Tissue & Energy, UCL, London, United Kingdom.
Darina KohoutovaResearch Department of Tissue & Energy, UCL, London, United Kingdom; Division of Gastrointestinal Services, University College Hospital, London, United Kingdom.
Charles A MosseResearch Department of Tissue & Energy, UCL, London, United Kingdom.
Gokhan YahiogluDepartment of Chemistry, Imperial College London, London, United Kingdom; PhotoBiotics Ltd, Chemistry Building, Imperial College London, London, United Kingdom.
Ioanna StamatiDepartment of Chemistry, Imperial College London, London, United Kingdom.
Mahendra DeonarainPhotoBiotics Ltd, Chemistry Building, Imperial College London, London, United Kingdom; Department of Life Sciences, Imperial College London, London, United Kingdom.
Sinan BattahOrganix Ltd, Colchester, United Kingdom; School of Biological Sciences, University of Essex, Colchester, United Kingdom.
Derren ReadyPublic Health Laboratory London, Pathology & Pharmacy Building, London, United Kingdom.
Elaine AllanMicrobial Diseases, UCL Eastman Dental Institute, London, United Kingdom.
Peter MullanyMicrobial Diseases, UCL Eastman Dental Institute, London, United Kingdom.
Laurence B LovatResearch Department of Tissue & Energy, UCL, London, United Kingdom; Division of Gastrointestinal Services, University College Hospital, London, United Kingdom.
University College London · GBEastman Dental Hospital · GBPhotoBiotics (United Kingdom) · GBUniversity College Hospital · GBImperial College London · GBUniversity of Essex · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClostridium difficile is the leading cause of antibiotic-associated diarrhoea and pseudo membranous colitis in the developed world. The aim of this study was to explore whether Photodynamic Antimicrobial Chemotherapy (PACT) could be used as a novel approach to treating C. difficile infections.

methodsPACT utilises the ability of light-activated photosensitisers (PS) to produce reactive oxygen species (ROS) such as free radical species and singlet oxygen, which are lethal to cells. We screened thirteen PS against C. difficile planktonic cells, biofilm and germinating spores in vitro, and cytotoxicity of effective compounds was tested on the colorectal adenocarcinoma cell-line HT-29.

resultsThree PS were able to kill 99.9% of bacteria in both aerobic and anaerobic conditions, both in the planktonic state and in a biofilm, after exposure to red laser light (0.2 J/cm2) without harming model colon cells. The applicability of PACT to eradicate C. difficile germinative spores indirectly was also shown, by first inducing germination with the bile salt taurocholate, followed by PACT.

conclusionThis innovative and simple approach offers the prospect of a new antimicrobial therapy using light to treat C. difficile infection of the colon.

Indexed as

PhotochemotherapyBiofilmsCell SurvivalChlorophyllidesClostridioides difficileHT29 CellsHumansMethylene BlueMicrobial Sensitivity TestsPhotosensitizing AgentsPorphyrinsChlorophyllidesMethylene BluePhotosensitizing AgentsphytochlorinPorphyrinsTalaporfin

Identifiers

PMID26313448
PMCPMC4551672
OpenAlexW1171766090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.